This compound is a designed molecule for use in biochemical research, particularly in proteolysis targeting chimeras (PROTACs), a technology that induces the degradation of unwanted target proteins within cells. It functions as a bifunctional linker that recruits the target protein to the ubiquitin-proteasome system, the cell's natural machinery for eliminating damaged or unnecessary proteins.

The structure features a specific binding moiety for the target protein (incorporating thiazole and oxazole rings with a tert-butyl group) and a cereblon E3 ligase recruiter (based on the 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl moiety), connected via a polyethylene glycol (PEG)-like linker with piperidine and urea elements. This enables ubiquitination of the target protein, leading to its proteasomal degradation. It holds potential for developing therapeutics against diseases involving aberrant or overexpressed proteins, such as cancer, neurodegenerative disorders, or protein misfolding conditions.

The complex structure, including the long oxygen-rich linker, enhances water solubility and cellular access. However, it remains in the research and development stage, with no clinical use yet, requiring further studies on safety, efficacy, and in vivo behavior.

This molecule is a specialty chemical, serving as a niche intermediate in advanced targeted degradation technologies for oncology and beyond.